107 related articles for article (PubMed ID: 32250153)
1. The performance of the
Xu Z; Wang Y; Wang L; Xiong J; Wang H; Cui F; Peng H
Biomark Med; 2020 Apr; 14(5):341-351. PubMed ID: 32250153
[No Abstract] [Full Text] [Related]
2. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
3. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
[TBL] [Abstract][Full Text] [Related]
4. [DNA methylation detection of SHOX2 and PTGER4 in plasma contributes to differential diagnosis of pulmonary nodule patients].
Chu X; Zhao W; Wang B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Apr; 35(4):357-361. PubMed ID: 31167696
[TBL] [Abstract][Full Text] [Related]
5. Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.
Schmidt B; Beyer J; Dietrich D; Bork I; Liebenberg V; Fleischhacker M
PLoS One; 2015; 10(2):e0118195. PubMed ID: 25675432
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of lung malignant epithelial cells by gene methylation analysis in the conditionally reprogrammed cell cultures.
Wu GD; Xiao YG; Fang FY; Yao D; Liu J; Cao YH; Mao Y; Yu B; Yao TR; Wu YM; Qian YH; Yu DH
Neoplasma; 2020 May; 67(3):692-699. PubMed ID: 32202907
[TBL] [Abstract][Full Text] [Related]
8. SHOX2 methylation in Vietnamese patients with lung cancer.
Vo TTL; Nguyen TN; Nguyen TT; Pham ATD; Vuong DL; Ta VT; Ho VS
Mol Biol Rep; 2022 May; 49(5):3413-3421. PubMed ID: 35088378
[TBL] [Abstract][Full Text] [Related]
9. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Ilse P; Biesterfeld S; Pomjanski N; Wrobel C; Schramm M
Cancer Genomics Proteomics; 2014; 11(5):251-8. PubMed ID: 25331797
[TBL] [Abstract][Full Text] [Related]
10. Cell-Free Methylated
Fleischhacker M; Arslan E; Reinicke D; Eisenmann S; Theil G; Kollmeier J; Schäper C; Grah C; Klawonn F; Holdenrieder S; Schmidt B
Diagnostics (Basel); 2023 Jun; 13(13):. PubMed ID: 37443525
[TBL] [Abstract][Full Text] [Related]
11. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
[TBL] [Abstract][Full Text] [Related]
12. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
[TBL] [Abstract][Full Text] [Related]
13. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates.
Dietrich D; Kneip C; Raji O; Liloglou T; Seegebarth A; Schlegel T; Flemming N; Rausch S; Distler J; Fleischhacker M; Schmidt B; Giles T; Walshaw M; Warburton C; Liebenberg V; Field JK
Int J Oncol; 2012 Mar; 40(3):825-32. PubMed ID: 22108652
[TBL] [Abstract][Full Text] [Related]
14. The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders.
Konecny M; Markus J; Waczulikova I; Dolesova L; Kozlova R; Repiska V; Novosadova H; Majer I
Neoplasma; 2016; 63(2):246-53. PubMed ID: 26774146
[TBL] [Abstract][Full Text] [Related]
15. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging.
Darwiche K; Zarogoulidis P; Baehner K; Welter S; Tetzner R; Wohlschlaeger J; Theegarten D; Nakajima T; Freitag L
Ann Oncol; 2013 Nov; 24(11):2866-70. PubMed ID: 24026539
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay.
Song L; Yu H; Li Y
Mol Diagn Ther; 2015 Jun; 19(3):159-67. PubMed ID: 26014676
[TBL] [Abstract][Full Text] [Related]
17. Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity.
Zang R; Wang X; Jin R; Lei Y; Huang J; Liu C; Zheng S; Zhou F; Wu Q; Sun N; Gao S; He J
J Transl Med; 2019 Dec; 17(1):430. PubMed ID: 31888670
[TBL] [Abstract][Full Text] [Related]
18. Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors.
Schneider KU; Dietrich D; Fleischhacker M; Leschber G; Merk J; Schäper F; Stapert HR; Vossenaar ER; Weickmann S; Liebenberg V; Kneip C; Seegebarth A; Erdogan F; Rappold G; Schmidt B
BMC Cancer; 2011 Mar; 11():102. PubMed ID: 21426551
[TBL] [Abstract][Full Text] [Related]
19. The
Peng X; Liu X; Xu L; Li Y; Wang H; Song L; Xiao W
J Thorac Dis; 2019 Jun; 11(6):2458-2469. PubMed ID: 31372283
[TBL] [Abstract][Full Text] [Related]
20. Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer.
Zhang Y; Huang J; Zou Q; Che J; Yang K; Fan Q; Qian D; Wu J; Bao E; Song L; Zhang F
Oncol Lett; 2020 Apr; 19(4):3229-3238. PubMed ID: 32256818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
